Using Iodine-124 PET scans to assess metastatic thyroid cancer treatment
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
This study is testing a new type of PET scan using iodine-124 to see how well it can help doctors decide on the best treatment for people with metastatic thyroid cancer.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT03647358 on ClinicalTrials.gov |
What this trial studies
This study evaluates a new diagnostic imaging test using positron emission tomography (PET) with iodine-124 to measure radioactive iodine uptake in metastatic thyroid carcinoma. If the test indicates sufficient uptake, standard treatment with radioiodine will continue; if not, alternative therapies may be considered. The study aims to improve treatment decisions for patients with thyroid cancer by providing more accurate dosimetry information. Participants will undergo PET/CT scans to assess their condition before therapy.
Who should consider this trial
Good fit: Ideal candidates include adults with confirmed metastatic thyroid carcinoma who have undergone total thyroidectomy and are planning to receive radioiodine therapy.
Not a fit: Patients under 18 years old or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with metastatic thyroid carcinoma.
How similar studies have performed: Other studies using similar imaging techniques have shown promise, but this specific approach with iodine-124 is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults with thyroid carcinoma confirmed by pathology. * Adult thyroid carcinoma patients who have undergone total thyroidectomy * Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care. * The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present. * All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning. Exclusion Criteria: * Age less than 18 years. * Patients who are pregnant.
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Ravinder Grewal, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Ravinder Grewal, MD
- Email: grewalr@mskcc.org
- Phone: 212-639-2872
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.